Physician profile
Peter Libby
NPI 1033161401
$42,735.30
in general payments reported to CMS, 2019-2025
14 companies · $1,933 in 2025
The $1,933 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $152 · 2022: $7,341 · 2023: $11K · 2024: $4,364 · 2025: $1,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $16K · Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $16,004.16 |
| Food and Beverage | $927.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharma Ag | $15,107.00 | 2019-2022 | |
| Novo Nordisk As | $9,370.91 | 2023-2024 | |
| Regeneron Pharmaceuticals, INC. | $7,436.47 | 2019 | |
| Abbott Laboratories | $3,640.14 | 2024 | Amplatzer |
| Amgen INC. | $3,265.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,224.73 | 2019-2024 | |
| Csl Behring | $1,034.28 | 2023 | |
| Kowa Company, Ltd. | $958.07 | 2019 | |
| Esperion Therapeutics, INC. | $193.66 | 2023 | Nexletol |
| Genentech, INC. | $180.05 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $152.02 | 2020 | |
| Abbvie INC. | $74.52 | 2023 | |
| Novartis Pharmaceuticals Corporation | $71.01 | 2023 | Leqvio |
| E.R. Squibb & Sons, L.L.C. | $26.75 | 2024 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Libby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.